Leading global drug delivery technology company Catalent Pharma Solutions has announced a major expansion of its controlled release drug manufacturing facility in Winchester, Kentucky.
The company is to invest nearly US$35m to expand the 100,000ft2 facility by almost 80,000ft2 of modern manufacturing space, and will add as many as 90 new employees at the expanded site. Catalent expects to complete the expansion by October 2014.
Opened in 1992, Catalent’s Winchester facility has evolved into a premier industry site for advanced oral controlled-release drug formulation and manufacturing, launching more than 100 products for Catalent’s pharmaceutical and consumer health customers.
The Winchester expansion comes on the heels of several significant investments Catalent has made in advanced delivery technologies globally. ‘Catalent has continued to build on its global leadership in advanced drug development solutions and advanced delivery technologies with major recent investments in controlled release forms, including fluid bed capacity, OptiMelt hot melt extrusion, and OSDRC OptiDose advanced tableting technologies,’ said Catalent President and CEO John Chiminski.
‘As with Winchester, Catalent continues to invest to meet the most critical needs of the industry, including recently announced inhalation facility expansion in North Carolina, our recently completed biologics expansion in Wisconsin, and our two new ventures in China, which will focus on softgel technologies and clinical trial supplies.’
